Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Eli Lilly

Vertex Pharmaceuticals

Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.

3 Growth Stocks to Buy and Hold

Inmode Ltd

Investing in growth stocks can be far less risky if you make smaller, more frequent purchases of your favorite companies. Axsome Therapeutics is a commercial-stage drugmaker that recently launched a new treatment for depression, one of the most commonly diagnosed disabilities.

2 Magnificent Growth Stocks You Can Buy With $150 Right Now

Axsome launched its first in-house developed drug last year -- the antidepressant Auvelity. In its first full quarter of commercialization, Auvelity reached more than 30,000 patients.

Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?

Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.

Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Mark Jacobson - Investor Relations Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Executive Vice President, Commercial and Business Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Marc Goodman - SVB Securities David Amsellem - Piper Sandler Joon Lee - Truist Securities Vikram Purohit - Morgan Stanley Yatin Suneja - Guggenheim Partners Joseph Thome - TD Cowen Graig Suvannavejh - Mizuho Securities Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Boobalan Pachaiyappan - H.C. Wainwright Operator Hello and welcome to the Axsome Therapeutics First Quarter 2023 Financial Results Conference Call and Webcast.

Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Call Transcript

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.03 per share a year ago.

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

Shares of Axsome Therapeutics and BioXcel Therapeutics diverged Monday after the duo reported first-quarter sales of their newest products. The post Axsome Surges As Its Newest Product Shines.

Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.

Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2023. “The first quarter of 2023 was another important milestone for Axsome as it marked the first full quarter of launch for Auvelity.

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference being held in Las Vegas, Nevada on Thursday, May 11, 2023, at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time.

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

Axsome Therapeutics, Inc. has a lot of good things happening. Axsome Therapeutics has the potential to become a large CNS-focused biopharma.

Axsome Therapeutics: Things Are Coming Together Nicely

One World Trade Center to be lit up in green in observance of Mental Health Month One World Trade Center to be lit up in green in observance of Mental Health Month

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

Altimmune

Biogen

The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy

CRISPR Therapeutics

Intellia Therapeutics

Investors have shown keen interest in biotech after Johnson & Johnson's (NYSE: JNJ ) impressive earnings beat that topped Wall Street's expectations. The earnings beat reignited enthusiasm for biotech stocks, prompting investors to search for the next big players.

3 Biotech Stocks to Watch After Johnson & Johnson's Earnings Beat

Axsome recently launched two potential blockbusters. At the same time, expenses are rising, and the company's net loss is widening.

Axsome Therapeutics Stock: Bear vs. Bull

Axsome Therapeutics has several major milestones around the corner. CRISPR Therapeutics could soon win approvals for its first product.

3 Stocks With Huge Catalysts on the Way

Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, being held from April 22-27 in Boston. These presentations include new data from the SHARP study, a randomized, double-blind, placebo-controlled, crossover, multicenter trial in 59 patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) and impaired cognitive function, from which positive topline results were announced in October 20221.

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of

Sana Biotechnology

Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.

The Top 3 Biotech Stocks to Watch in 2023

Tandem Diabetes Care

Axsome is expecting important developments that should improve its already-bright prospects. Tandem's innovative insulin pump should allow it to capture a larger share of the diabetes market.

2 Beaten-Down Growth Stocks to Buy in April

Axsome just launched two treatments, Sunosi and Auvelity, and it could launch two others soon. It will take a while for sales to ramp up, and for the company to turn a profit.

1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally

Axsome Therapeutics: A Prescription For Success In The CNS Space

Axsome Therapeutics stock has generated significant gains over the past year. Analysts still see much more upside thanks to the biotech's growth potential.

Could Axsome Therapeutics Stock Help You Become a Millionaire?

Axsome last year launched two products that could bring in revenue of more than $1 billion each. CRISPR Therapeutics recently completed regulatory requests for its first potential product.

Better Growth Stock: Axsome vs. CRISPR Therapeutics

Axsome's stock trounced the market over the last 12 months. The biotech is ramping up sales of two recently approved therapies.

Is It Too Late to Buy Axsome Therapeutics Stock?

Intuitive Surgical

Moderna

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

News for Axsome Therapeutics Stock (AXSM)